Novel Therapeutic Approaches to Tuberculosis

This symposium will explore novel strategies to treat tuberculosis, either through direct antimicrobial interventions or the manipulation of host immunity. The sessions will explore three topical areas:
• The mechanisms underlying the inflammatory response to M. tuberculosis, and novel strategies to ameliorate disease through the manipulation of this response.
• New approaches to accelerate TB chemotherapy, concentrating on genetic/chemical synergies, specific targeting of persistent bacterial populations, and host-directed antimicrobial therapies.
• Immunotherapy for both latent and active disease, with an emphasis on cytokine modulation and therapeutic vaccines. This symposium will assemble a diverse group of scientists specializing in immunology, bacteriology, cell biology, and therapeutic development. To ensure that insights from basic science are discussed in the context of practical therapeutic solutions, attendees will be drawn from both academic and industrial institutions. A particular emphasis will be placed on lessons gleaned from other systems, such as cancer, acute inflammation, and viral infections, which could be applied to tuberculosis. This diversity of background and approach will encourage the development of truly novel approaches to treat this devastating disease.
+ show speakers and program
Sunday, March 30
Arrival and Registration Longs Peak Foyer

Monday, March 31
Keynote Address: Charles N. Serhan, Brigham and Women's Hospital, USA
Regulation of Acute Inflammation and Resolution: Lessons from Lipid Mediators

AM Plenary: Inflammation: Balance between Bacterial Control and Immunopathology
David M. Tobin, Duke University Medical Center, USA
Eicosanoid Balances Determine TB Disease Progression
Andrea M. Cooper, Trudeau Institute, USA
Regulation of Pathology Helen A. Fletcher, University of Oxford, UK
Role of Myeloid Signatures in the Prediction of Active Tuberculosis
Short Talk(s) Chosen from Abstracts

Workshop 1: Targeting Host Pathways and Immunity
Short Talks Chosen from Abstracts

PM Plenary: Strategies to Ameliorate Lung Damage
Paul T. Elkington, University of Southampton, UK
Targeting Matrix Metalloproteinase Activity to Reduce Immunopathology
Samuel M. Behar, Brigham and Women's Hospital, USA
Tissue-Protective Activities of Anti-Microbial Immune Responses
Speaker to be Announced
Short Talk Chosen from Abstracts

Poster Session 1

Tuesday, April 1
AM Plenary: Novel Antimicrobial Strategies
Lalita Ramakrishnan, University of Washington, USA
Overcoming Environmentally-Induced Drug Tolerance
Terry Roemer, Merck, USA
Exploiting Chemical and Genetic Synergies to Improve Antibiotic Activity
William R. Bishai, Johns Hopkins School of Medicine, USA and K-RITH, South Africa, USA
Immunomodulation during Therapy
Speaker to be Announced
Short Talk(s) Chosen from Abstracts

PM Plenary: Host-Directed Antimicrobial Therapies
Kanury V. S. Rao, International Centre for Genetic Engineering and Biotechnology, India
Manipulating Host-Pathogen Crosstalk to Treat TB Infection
Daniel Kalman, Emory University, USA
Repurposing Host-Directed Drugs to Treat Infectious Disease
Robert J. Wilkinson, University of Cape Town, South Africa
The Interaction between Antimicrobial and Adjunctive Therapies and the Immune Response to Tuberculosis
Short Talk(s) Chosen from Abstracts

Wednesday, April 2
AM Plenary: Targeting Persistent Bacterial Populations
Tawanda Gumbo, University of Texas Southwestern Medical Center, USA
Accelerating the Kill of Tuberculosis Persisters: The Interaction of Drug Concentration and Novel Bacterial Complex Adaptive Systems
Stewart T. Cole, École Polytechnique Fédérale de Lausanne, Switzerland
Eradicating Persistent Bacteria
Christopher M. Sassetti, University of Massachusetts Medical School, USA
Bacterial Adaptations to the Host Environment
Speaker to be Announced
Short Talk(s) Chosen from Abstracts

Workshop 2: Targeting the Bacterium
Short Talks Chosen from Abstracts

PM Plenary: Therapy for Latent TB Infection Grays Peak
Gavin J. Churchyard, Aurum Institute, South Africa
Community/Population-Based Interventions for LTBI
Peter Andersen, Statens Serum Institut, Denmark
Development of an LTBI Vaccine
David M. Margolis, University of North Carolina at Chapel Hill, USA
Eradication of Latent Pathogens: Lessons from HIV
Short Talk(s) Chosen from Abstracts

Poster Session 3

Thursday, April 3
AM Plenary: Immunotherapy for Active Disease Grays Peak
Alan Sher, NIAID, National Institutes of Health, USA
Understanding and Modulating TB Disease
Anne O'Garra, MRC National Institute for Medical Research, UK
Biology and Therapeutic Potential of IL-10 Modulation
Gilla Kaplan, Public Health Research Institute, UMDNJ, USA
Changing the Course of TB Pathogenesis and Treatment
Steven Holland, NIAID, National Institutes of Health, USA
Genetic Determinants of Reactivation
Short Talk(s) Chosen from Abstracts

PM Plenary: Therapeutic Vaccines Grays Peak
Thomas G. Evans, Aeras Global TB Vaccine Foundation, USA
Issues and Controversies Surrounding Ongoing Therapeutic Vaccine Trials
Geneviève Inchauspe, Transgène, France
Immune Modulation in Latent and Active Disease through Vaccination
Rhea N. Coler, Infectious Disease Research Institute, USA
Preclinical and Clinical Testing of a Therapeutic Vaccine
Short Talk Chosen from Abstracts

Friday, April 4
Departure

30 Mar - 4 Apr 2014
Keystone
United States of America
meeting website